RSS   Newsletter   Contact   Advertise with us

SAGE Therapeutics appoints Michael Cola to board

Staff writer | Cambridge, Mass., USA | September 17, 2014
SAGE TherapeuticsSeptember 17, 2014, Cambridge, Mass., USA - SAGE Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Michael F. Cola to the company's board of directors.
Mr. Cola currently serves as president and chief executive officer of Medgenics, Inc. Prior to joining Medgencis, he served as president of specialty pharmaceuticals at Shire plc, a global specialty pharmaceutical company he first joined in 2005 as executive vice-president of global therapeutic business units and portfolio management.

Previously, Mr. Cola also served as a growth capital provider and president of the life sciences group for Safeguard Scientifics, Inc., where he served as chairman and chief executive officer of Clarient, Inc., and chairman of Laureate Pharma, Inc.

In addition, Mr. Cola has held senior positions in product development and commercialization at AstraMerck and AstraZeneca.

Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He also serves on the board of directors at Vanda Pharmaceuticals Inc. and Pennsylvania BIO.


 LATEST MOVES FROM Massachusetts 


MORE INSIDE POST